Molecular Templates
Biotechnology, 9301 Amberglen BLVD Ste 100, Austin, Texas, 78729, United States, 11-50 Employees
Phone Number: 51********
Who is MOLECULAR TEMPLATES
Molecular Templates, Inc. (MTEM) is a clinical stage biopharmaceutical company focused on the discovery and development of biologic therapeutics for the treatment of cancer and other seri...
Read More
-
Headquarters: 9301 Amberglen BLVD Ste 100, Austin, Texas, 78729, United States
-
Date Founded: 2001
-
Employees: 11-50
-
Revenue: $10 Million to $25 Million
-
Active Tech Stack: See technologies
Industry: Biotechnology
SIC Code: 2834
Does something look wrong? Fix it. | View contact records from MOLECULAR TEMPLATES
Molecular Templates Org Chart and Mapping
Email
Phone
Sign in to CIENCE GO Data to uncover contact details
Free credits every month
Frequently Asked Questions Regarding Molecular Templates
Answer: Molecular Templates's headquarters are located at 9301 Amberglen BLVD Ste 100, Austin, Texas, 78729, United States
Answer: Molecular Templates's phone number is 51********
Answer: Molecular Templates's official website is https://mtem.com
Answer: Molecular Templates's revenue is $10 Million to $25 Million
Answer: Molecular Templates's SIC: 2834
Answer: Molecular Templates has 11-50 employees
Answer: Molecular Templates is in Biotechnology
Answer: Molecular Templates contact info: Phone number: 51******** Website: https://mtem.com
Answer: Molecular Templates, Inc. (MTEM) is a clinical stage biopharmaceutical company focused on the discovery and development of biologic therapeutics for the treatment of cancer and other serious diseases. The company primarily develops a pipeline of therapies through its proprietary biologic engineered toxin body (ETB) drug platform with unique mechanisms of actions which are highly differentiated from antibody drug conjugates (ADCs). MTEM is developing MT-6402, which is in a Phase I clinical trial for PD-1/PD-L1 antibody relapsed/refractory patients; MT-5111, which is in a Phase I clinical trial for the treatment of HER2-positive cancers; and MT-0169, which is in a Phase I clinical trial to treat relapsed/refractory myeloma. MTEMs pipeline of ETBs in development for other targets include CTLA-4, TIGIT, TROP2, and BCMA. MTEM has a collaboration agreement with Bristol Myers Squibb to discover and develop novel products containing ETBs directed to multiple targets. Molecular Templates, Inc. was founded in 2001 and is headquartered in Austin, Texas.
Premium Sales Data for Prospecting
-
Sales data across over 200M records
-
Up-to-date records (less decayed data)
-
Accurate Email Lists (real-world tested)
-
Powerful search engine and intuitive interface
Get Full Access
Sign in to CIENCE GO Data to uncover contact details
Free credits every month